Press Release: Sarclisa® (isatuximab) plus KRd signific

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Related Keywords

Spain , Netherlands , Greece , Czech Republic , Denmark , United States , Paris , France General , France , Switzerland , Turkey , Austria , United Kingdom , Norway , Italy , Germany , American , Peterc Adamson , Sally Bain , Pieter Sonneveld , Nathalie Pham , Felix Lauscher , Corentine Driancourt , Tarik Elgoutni , Eva Schaefer Jansen , European Myeloma Network , Nasdaq , Department Of Molecular Biotechnology , International Myeloma Working Group , European Union , American Society Of Hematology , University Of Torino , Euronext , University Division Of Hematology , Drug Administration , Global Development Head , Health Sciences , American Society , Annual Meeting , Francesca Gay , Associate Professor , University Division , Molecular Biotechnology , Development Head , Nonproprietary Naming , Biological Products Guidance , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,